Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal

publication date: Feb 14, 2023

A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pharma in a heavily backloaded $692.5 million deal. Corbus will have rights to SYS6002 in the US, EU and Australian markets. CSPC Megalith Biopharma has started a China Phase I dose-escalating trial of the candidate in patients with advanced solid tumor cancers. CSPC will receive a $7.5 million upfront payment and up to $685 million in milestones, plus royalties on sales. CSPC plans to aim SYS6002 at urothelial cancer initially. More details....

Stock Symbols: (HK: 01093) (NSDQ: CRBP)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital